sorafenib has been researched along with emd1214063 in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (emd1214063) | Trials (emd1214063) | Recent Studies (post-2010) (emd1214063) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 76 | 11 | 73 |
| Protein | Taxonomy | sorafenib (IC50) | emd1214063 (IC50) |
|---|---|---|---|
| Hepatocyte growth factor receptor | Homo sapiens (human) | 0.0048 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, M; He, J; Jiang, X; Jiang, Y; Li, J; Liu, J; Ouyang, L; Wang, J; Zhang, J; Zhang, S | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Assenat, E; Barone, C; Berghoff, K; Blanc, JF; Bruns, R; Decaens, T; Faivre, S; Fasolo, A; Grando, V; Iacobellis, A; Merle, P; Raymond, E; Scheele, J; Straub, J; Trojan, J; Villa, E; Wermke, M | 1 |
| Berghoff, K; Cheng, AL; Choi, HJ; Kim, JH; Kim, TY; Lim, HY; Pan, H; Park, JW; Qin, S; Rau, KM; Ren, Z; Ryoo, BY; Scheele, J; Straub, J; Yen, CJ; Zhou, D | 1 |
1 review(s) available for sorafenib and emd1214063
| Article | Year |
|---|---|
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Drug Discovery; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Small Molecule Libraries | 2016 |
2 trial(s) available for sorafenib and emd1214063
| Article | Year |
|---|---|
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Proto-Oncogene Proteins c-met; Pyridazines; Pyrimidines; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation; Young Adult | 2021 |
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Topics: Administration, Oral; Adult; Aged; Asian People; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-met; Pyridazines; Pyrimidines; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation | 2021 |
1 other study(ies) available for sorafenib and emd1214063
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |